Idarubicin hcl - @ Anthracycline antibiotics
Drug Name:Idarubicin hcl - @ Anthracycline antibiotics
List Of Brands:
Indication Type Description:
Drug Interaction
Indication
Adverse Reaction
Contra-Indications
Dosages/ Overdosage Etc
Patient Information
Pharmacology/ Pharmacokinetics
Pregnancy and lactation
Drug Interaction:
None reported
Indication:
Adverse Reaction:
Nausea and vomiting, hair loss, abdominal cramps, hemorrhage, mucositis, fever, headache, seizure, pulmonary allergy.
IDR DNR IDR - Idarubicin DNR - Daunorubicin Infection 95% 97% Nausea and vomiting 82% 80% Hair loss 77% 72% abdominal cramps 73% 68% haemorrhage 63% 65% mucositis 50% 55% dermatologic 46% 40% mental status 41% 34% pulmonary -clinical 39% 39% fever 26% 28% headache 20% 24% cardiac -clinical 16% 24% neurological - peripheral nerves 7% 9% seizure 4% 5% cerebellar 4% 4% pulmonary allergy 2%
Contra-Indications:
None reported
Special precuations:
Monitoring- Laboratory monitoring, hyperuricemia. Administer slowly. frequent complete blood counts and monitoring of heparin and renal function tests recommend
Heperuricema- Ttake appropiate measures to prevent hyperuricemia and to control any systemic infection before beginning surgery
Admininster- Slowly ( over 10 t0 15 minutes ) into tubing of a freely running IV infusion of 0.9% sodium chloride injection, USP or 5% dextrose injection USP
Warnings
Bone marrow suppression- Do not give to patients with pre-existing bone marrow suppresion induced by previous drug therapy or radiotherapy unless the benefits warrant risk
Severe myelosuppression- Will occur in all patients given a therapeutic dose of the agent for induction, consolidation or maintenance. Careful monitoring is required
Cardiotoxicity- Carefully monitor cardiac function during treatment in order to minimise risk of cardiac toxicity Pregnancy Advice women of child bearing potential to avoid pregnancy
Lactation- Mothers should discontinue nursing prior to taking this drug
Dosages/ Overdosage Etc:
Patient Information:
Pharmacology/ Pharmacokinetics:
Pharmacology:
Idarubicin hcl is a synthetic antineoplastic anthracycline for IV use. It is a DNA -intercallating analog of daunorubicin which has an inhibitory effect on nucleic acid synthesis and intercats with the enzyme topoisomerase II.
Pharmacokinetics:
The drug is eliminated predominantly by biliary and to a lesser extent by renal excretion, mostly in the form of primary metabolite 13-dihydroxydarubicin (idarubinol).
Pregnancy and lactation:
Pregnancy:
Use caution and advise women of child bearing potential to avoid pregnancy
Lactation: Advise mothers to discontinue nursing prior to taking this drug.
